Cargando…
Podcast on B Cell-Targeting Therapies and Other Multiple Sclerosis Concerns During COVID-19
The ongoing coronavirus disease 2019 (COVID-19) pandemic continues to raise questions for people living with multiple sclerosis (MS) and their healthcare providers. Common questions have included whether people living with MS are at higher risk of COVID-19 or of severe disease, whether certain disea...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784023/ https://www.ncbi.nlm.nih.gov/pubmed/35066816 http://dx.doi.org/10.1007/s40120-021-00321-9 |
_version_ | 1784638656978354176 |
---|---|
author | Shin, Robert K. Repovic, Pavle Berger, Joseph R. |
author_facet | Shin, Robert K. Repovic, Pavle Berger, Joseph R. |
author_sort | Shin, Robert K. |
collection | PubMed |
description | The ongoing coronavirus disease 2019 (COVID-19) pandemic continues to raise questions for people living with multiple sclerosis (MS) and their healthcare providers. Common questions have included whether people living with MS are at higher risk of COVID-19 or of severe disease, whether certain disease-modifying therapies (DMTs) for MS heighten COVID-19 risk, and if/how COVID-19 vaccinations should be administered in relation to MS treatments. Anti-CD20 therapies, which target B cells, have been of particular interest given the role B cells play in the response to both the virus that causes COVID-19 (SARS-CoV-2) and vaccines. As more data surfaces and the pandemic evolves, additional questions have emerged regarding the administration of booster shots and differences between B cell-targeting therapies and other DMTs in terms of their immunomodulatory effects. In this podcast article, MS specialists discuss these challenges to MS care during the COVID-19 pandemic and the recent data which are currently informing their clinical decision-making. As the pandemic evolves, providers should continually partner with people living with MS to achieve MS treatment goals informed by the latest developments in COVID-19. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40120-021-00321-9. |
format | Online Article Text |
id | pubmed-8784023 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-87840232022-01-24 Podcast on B Cell-Targeting Therapies and Other Multiple Sclerosis Concerns During COVID-19 Shin, Robert K. Repovic, Pavle Berger, Joseph R. Neurol Ther Commentary The ongoing coronavirus disease 2019 (COVID-19) pandemic continues to raise questions for people living with multiple sclerosis (MS) and their healthcare providers. Common questions have included whether people living with MS are at higher risk of COVID-19 or of severe disease, whether certain disease-modifying therapies (DMTs) for MS heighten COVID-19 risk, and if/how COVID-19 vaccinations should be administered in relation to MS treatments. Anti-CD20 therapies, which target B cells, have been of particular interest given the role B cells play in the response to both the virus that causes COVID-19 (SARS-CoV-2) and vaccines. As more data surfaces and the pandemic evolves, additional questions have emerged regarding the administration of booster shots and differences between B cell-targeting therapies and other DMTs in terms of their immunomodulatory effects. In this podcast article, MS specialists discuss these challenges to MS care during the COVID-19 pandemic and the recent data which are currently informing their clinical decision-making. As the pandemic evolves, providers should continually partner with people living with MS to achieve MS treatment goals informed by the latest developments in COVID-19. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40120-021-00321-9. Springer Healthcare 2022-01-23 /pmc/articles/PMC8784023/ /pubmed/35066816 http://dx.doi.org/10.1007/s40120-021-00321-9 Text en © The Author(s) 2022, corrected publication 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Commentary Shin, Robert K. Repovic, Pavle Berger, Joseph R. Podcast on B Cell-Targeting Therapies and Other Multiple Sclerosis Concerns During COVID-19 |
title | Podcast on B Cell-Targeting Therapies and Other Multiple Sclerosis Concerns During COVID-19 |
title_full | Podcast on B Cell-Targeting Therapies and Other Multiple Sclerosis Concerns During COVID-19 |
title_fullStr | Podcast on B Cell-Targeting Therapies and Other Multiple Sclerosis Concerns During COVID-19 |
title_full_unstemmed | Podcast on B Cell-Targeting Therapies and Other Multiple Sclerosis Concerns During COVID-19 |
title_short | Podcast on B Cell-Targeting Therapies and Other Multiple Sclerosis Concerns During COVID-19 |
title_sort | podcast on b cell-targeting therapies and other multiple sclerosis concerns during covid-19 |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784023/ https://www.ncbi.nlm.nih.gov/pubmed/35066816 http://dx.doi.org/10.1007/s40120-021-00321-9 |
work_keys_str_mv | AT shinrobertk podcastonbcelltargetingtherapiesandothermultiplesclerosisconcernsduringcovid19 AT repovicpavle podcastonbcelltargetingtherapiesandothermultiplesclerosisconcernsduringcovid19 AT bergerjosephr podcastonbcelltargetingtherapiesandothermultiplesclerosisconcernsduringcovid19 |